Related references
Note: Only part of the references are listed.Dual-Sensitivity Multiple Sclerosis Lesion and CSF Segmentation for Multichannel 3T Brain MRI
Dominik S. Meier et al.
JOURNAL OF NEUROIMAGING (2018)
Plasma neurofilament light chain levels in patients with MS switching from injectable therapies to fingolimod
Fredrik Piehl et al.
MULTIPLE SCLEROSIS JOURNAL (2018)
Plasma neurofilament light chain levels in patients with MS switching from injectable therapies to fingolimod
Fredrik Piehl et al.
MULTIPLE SCLEROSIS JOURNAL (2018)
Neurofilament light chain predicts disease activity in relapsing-remitting MS
Kristin N. Varhaug et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2018)
Cerebrospinal fluid biomarkers of inflammation and degeneration as measures of fingolimod efficacy in multiple sclerosis
Lenka Novakova et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
Cerebrospinal fluid biomarkers of inflammation and degeneration as measures of fingolimod efficacy in multiple sclerosis
Lenka Novakova et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
Neurofilament light chain in cerebrospinal fluid and prediction of disease activity in clinically isolated syndrome and relapsing-remitting multiple sclerosis
I. Hakansson et al.
EUROPEAN JOURNAL OF NEUROLOGY (2017)
Validity of the Symbol Digit Modalities Test as a cognition performance outcome measure for multiple sclerosis
Ralph H. B. Benedict et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
Serum neurofilament light in familial Alzheimer disease A marker of early neurodegeneration
Philip S. J. Weston et al.
NEUROLOGY (2017)
Serum neurofilament is associated with progression of brain atrophy and disability in early MS
Jens Kuhle et al.
NEUROLOGY (2017)
Monitoring disease activity in multiple sclerosis using serum neurofilament light protein
Lenka Novakova et al.
NEUROLOGY (2017)
Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease
Niklas Mattsson et al.
JAMA NEUROLOGY (2017)
Validity of the Symbol Digit Modalities Test as a cognition performance outcome measure for multiple sclerosis
Ralph H. B. Benedict et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
Exploration of machine learning techniques in predicting multiple sclerosis disease course
Yijun Zhao et al.
PLOS ONE (2017)
Serum Neurofilament Light: A Biomarker of Neuronal Damage in Multiple Sclerosis
Giulio Disanto et al.
ANNALS OF NEUROLOGY (2017)
Neurofilament Levels as Biomarkers in Asymptomatic and Symptomatic Familial Amyotrophic Lateral Sclerosis
Patrick Weydt et al.
ANNALS OF NEUROLOGY (2016)
The Effect of Fingolimod on Conversion of Acute Gadolinium-Enhancing Lesions to Chronic T1 Hypointensities in Multiple Sclerosis
Vinit V. Oommen et al.
JOURNAL OF NEUROIMAGING (2016)
Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa
Jens Kuhle et al.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2016)
Central fatigue in multiple sclerosis: a review of the literature
Pamela Newland et al.
JOURNAL OF SPINAL CORD MEDICINE (2016)
Neurofilament in CSFA biomarker of disease activity and long-term prognosis in multiple sclerosis
Per Soelberg Sorensen et al.
MULTIPLE SCLEROSIS JOURNAL (2016)
Neurofilament Light Chain in Blood and CSF as Marker of Disease Progression in Mouse Models and in Neurodegenerative Diseases
Mehtap Bacioglu et al.
NEURON (2016)
Neurofilament in CSFA biomarker of disease activity and long-term prognosis in multiple sclerosis
Per Soelberg Sorensen et al.
MULTIPLE SCLEROSIS JOURNAL (2016)
The prognostic value of CSF neurofilaments in multiple sclerosis at 15-year follow-up
Axel Petzold
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2015)
Glial and neuronal markers in cerebrospinal fluid predict progression in multiple sclerosis
M. Alba Mane Martinez et al.
MULTIPLE SCLEROSIS JOURNAL (2015)
Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis
Jens Kuhle et al.
NEUROLOGY (2015)
Glial and neuronal markers in cerebrospinal fluid predict progression in multiple sclerosis
M. Alba Mane Martinez et al.
MULTIPLE SCLEROSIS JOURNAL (2015)
Serum neurofilament light chain is a biomarker of human spinal cord injury severity and outcome
Jens Kuhle et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2015)
Neurofilament light antibodies in serum reflect response to natalizumab treatment in multiple sclerosis
Sandra Amor et al.
MULTIPLE SCLEROSIS JOURNAL (2014)
Increased Neurofilament Light Chain Blood Levels in Neurodegenerative Neurological Diseases
Johanna Gaiottino et al.
PLOS ONE (2013)
Axonal Damage in Relapsing Multiple Sclerosis is Markedly Reduced by Natalizumab
Martin Gunnarsson et al.
ANNALS OF NEUROLOGY (2011)
Diagnostic Criteria for Multiple Sclerosis: 2010 Revisions to the McDonald Criteria
Chris H. Polman et al.
ANNALS OF NEUROLOGY (2011)
Neurofilament light as a prognostic marker in multiple sclerosis
Jonatan Salzer et al.
MULTIPLE SCLEROSIS JOURNAL (2010)
The Challenge of Multiple Sclerosis: How Do We Cure A Chronic Heterogeneous Disease?
Howard L. Weiner
ANNALS OF NEUROLOGY (2009)
Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosis
C. E. Teunissen et al.
NEUROLOGY (2009)
A model for the comprehensive investigation of a chronic autoimmune disease: The multiple sclerosis CLIMB study
Susan A. Gauthier et al.
AUTOIMMUNITY REVIEWS (2006)
The relationship between diffuse axonal damage and fatigue in multiple sclerosis
MC Tartaglia et al.
ARCHIVES OF NEUROLOGY (2004)
Fatigue and declines in cognitive functioning in multiple sclerosis
LB Krupp et al.
NEUROLOGY (2000)